TPS, thymidine kinase, VEGF and endostatin in cytosol of thyroid tissue samples

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1517-1521

  Pikner, Richard ^a   Ludvikova M ^a   Ryska A ^a   Kholova I ^a   Holubec Jr , L ^a   Topolcan O ^a   Pecen, L ^a   Finek J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cytosol; Endostatin; Thymidine kinase; Thyroid gland; TPS; VEGF

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 18 FRAGMENT; ENDOSTATIN; MOLECULAR MARKER; PEPTIDE FRAGMENT; THYMIDINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOSOL; DNA SYNTHESIS; GOITER; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLIC RATE; PRIORITY JOURNAL; THYROID ADENOMA; THYROID CARCINOMA; THYROID DISEASE;

CYTOSOL; ENDOSTATINS; HUMANS; THYMIDINE KINASE; THYROID DISEASES; THYROID GLAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 21244483528     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Ishiwata T, Iino Y, Takei H, Oyama T and Morishita Y: Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep 5: 1343-1348, 1998.
2. Segal K, Shpitzer T, Feinmesser M, Stern Y and Feinmesser R: Angiogenesis in follicular tumors of the thyroid. J Surg Oncol 63: 95-98, 1996.
3. Wang J F, Milosveski V, Schramek C et al: Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 757: 5-12, 1998.
4. Ramsden JD: Angiogenesis in the thyroid gland. J Endocrinol 766: 475-480, 2000.
5. Hannigan BM, Barnett YA, Armstrong DB, McKelvey- Martin VJ and McKenna PG: Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biother 8: 189-197, 1993.
6. Gronowitz JS, Kallander FR, Diderholm H, Hagberg H and Pettersson U: Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 33: 5-12, 1984.
7. Saaristo A, Karpaneen T and Alitalo K: Mechanisms of angiogenesis and their use in inhibition of tumor growth and metastasis. Oncogene 79: 6122-6129, 2000.
8. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
9. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
10. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
11. O'Reilly MS, Boehm T, Shing Y et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
12. Klein M, Picard E, Vignaud J M et al: Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 767: 41-49, 1999.
13. Huang SM, Lee J CH, Wu TJ et al: Clinical relevance of vascular endothelial factor for thyroid neoplasms. World J Surg 25: 302-306, 2001.
14. Shushanov S, Bronstein M, Adélaide J et al: VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer 86: 47-52, 2000.
15. Revision of standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513-1519, 1980.
16. Makoto I, Shiro M, Kayo Y et al: Increased serum vascular endothelial growth factor levels and inthrathyroidal vascular area in patients with Graves' Disease and Hashimoto's thyroiditis. J Clin Endocrinol 83: 3908-3912, 1998.
17. Huang S, Lee J, Wu T and Chow N: Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 25: 302-306, 2001.
18. Dittati R, Meo S et al: Validation of blood collection procedures for determination of circulating VEGF in different blood samples. Int J Biol Markers 16: 2, 87-96, 2001.